Praxis Precision Medicines, Inc.’s Post

If essential tremor is causing shaky hands, consider an at-home research study evaluating an investigational drug for ET. https://bit.ly/47i6QqF #clinicaltrial #essentialtremor #MoreThanTremor #Essential3

Check out my latest article, "FDA’s New Draft Guidance for Psychedelic Drugs Opens Doors for Drug Developers in the US," published in the Journal for Clinical Studies. Step by step... https://lnkd.in/dtqqimPZ

Check out this interesting discussion on clinical research and drug regulation in the challenging times of individualized therapies: https://lnkd.in/dfukCNZD #ClinicalPharmacology #PharmacolRes #OpenAccess #Research 

How to Conduct Effective Generic Drug Clinical Studies https://lnkd.in/eMkhz-z9

PN Update: ICH adopts M12 guideline on drug interaction studies, releases draft M14 guidance on RWD

Organoids Stand Out as Stand Ins in Drug Development https://buff.ly/4aJ9APq #drugdevelopment #clinicaldevelopment #futuremedicine #organoids

Have you ever wondered why chloro- and methoxy-groups are so prevalent in FDA-approved drugs and clinical candidates? If you're interested in a deeper understanding of the specific drug-protein interactions and the impact these substituents have on drug properties, we highly recommend watching Yoshihiro Ishihara's insightful Flash Talk, "The Roles of Chloro- and Methoxy Groups in Drug Discovery," available on our YouTube channel https://lnkd.in/gbFbssdw For those curious about slides and the Q&A session, including questions we didn’t have time to address during the talk, Yoshihiro Ishihara has graciously shared his slides and prepared a comprehensive Q&A for our premium members. You can find the slides and the answers to all questions on his talk here: https://lnkd.in/g9MrCr47. Not a Drug Hunter member yet? Reach out to us here: https://lnkd.in/gDuQVXJ5.

Peritendinous adhesion: Therapeutic targets and progress of drug therapy. Read the article here: https://lnkd.in/gKNsvqud

Investigational drugs that exhibit CYP3A induction or inhibition are likely candidates for a combined oral contraceptives (COC) drug interaction study. The following white paper in our drug-drug interaction (DDI) series, “Women’s Health: Maximizing Study Design of Combined Oral Contraceptives Drug Interaction Studies” summarizes study designs that safely and efficiently assess a COC DDI effect. Read now > https://lnkd.in/gDGkk96 #Celerion #DrugDrugInteractions #ClinicalTrials #DrugDevelopment

Your investigational drug proved safe in Phase 1 and it’s on to Phase 2. Learn how we can help. https://buff.ly/2TUIzni